苦参素联合熊去氧胆酸对慢性乙型肝炎GGT的疗效观察被引量：1

The Observation of the Ppatients with Sophora Flavescens Elements and UDCA

下载PDF

导出

摘要目的探讨苦参素联合熊去氧胆酸(UDCA)治疗GGT持续升高的慢乙肝患者的疗效。方法治疗组47例给予UDCA联合苦参素治疗,对照组39例只用苦参素治疗,疗程2周。观察治疗组与对照组血清GGT值的变化。结果慢乙肝中度患者中,治疗组与对照组治疗后GGT值相比有明显差异(P<0.05)。结论应用UDCA和苦参素治疗慢性乙型肝炎能有效降低GGT,且无明显副作用。 Purpose： For exploring the treatment of the patients suffering from chronic hepatitis B with the two drugs. Methods： For the treatment group, 47 patients should be treated with the two drugs, and for the comparison group, 39patients should be treated only with the sophora flavescens elements, the period is about two weeks. After this, the results of the GGT should be observed, conclusion： GGT value has reasonable differences （P〈0.05） with the two treatments. Result： Using the two drugs, chronic B can be reduced obviously, and has no bad effects.

作者朱蓓徐瀚峰

机构地区江苏泰州职业技术学院医学系山东大学医学院

出处《泰州职业技术学院学报》 2005年第6期58-59,共2页 Journal of Taizhou Polytechnic College

关键词慢性乙型肝炎苦参素熊去氧胆酸治疗 chronic hepatitis B sophora flavescens, UDCA treatment

分类号 R512 [医药卫生—内科学]

引文网络
相关文献

参考文献3

1中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量：14007
2于岩岩,王勤环,朱理珉,张清波,徐道振,郭雁宾,王兆荃,郭树华,周霞秋,张玲霞.苦参素治疗慢性乙型肝炎的临床研究[J].中华肝脏病杂志,2002,10(4):280-282. 被引量：93
3李光明,谢青,周霞秋.熊去氧胆酸在慢性肝病中的应用及机制[J].肝脏,2002,7(1):59-61. 被引量：22

二级参考文献17

1[1]Goulis J. Leandro G. Burroughs AK. Randomised controlled trials of ursodeoxycholic acid therapy for pimary biliary cirrosis: a mata-analy-sis. Lancet, 1999,354:1053-1060.
2[2]Corpechot C, Carrat F, Bonnand AM, et al. The detect of ursodeoxzycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology,2000,32: 1196-1199.
3[3]Almasio PL, Floreani A, Chiaramonte M, et al. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicines in symptomatic primary biliary cirrhosis. Aliment Pharmacol Ther, 2000,14:1645-1652.
4[4]Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholicacid for treatment of primary biliary cirrhosis: results of a prospective double blind trial. Gastroenterology. 1999,117:918-925.
5[5]Lindor KD. Ursodiol for primary sclerosing cholangitis. N Eng1 J Med, 1997,336: 691-695.
6[6]van Hoogstraten H J, Vleggaar FP, Boland G J, et al. Budesonide or prednisone in combination with ursodeoxycholi acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Am J Gastroenterol, 2000,95: 2015-2022.
7[7]Gilger MA, Gann ME, Opekun AR, et al. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J Pediatr Gastroenterol Nutr, 2000,31: 136-141.
8[8]Palma J, Lentze H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: randomized double study controlled with placebo. J Hepatol, 1997,27:1022-1028.
9[9]Berkane N, Cocheton JJ, Brehier D, et al. Ursodeoxycholic acid in intrahepatic cholesasis of pregnancy. A retrospective study of 19 cases. Acta Obstet Gynecol Scand, 2000,79: 941-946.
10[10]Nousia-Arvanitakis S, Fotoulaki M, Economou H, et al. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosisrelated liver disease. J Clin Gastroenterol, 2001,32: 324-328.